Category Archives: R&D

Government-Funded Research: Is It That Different?

By Guest Blogger | Published: February 2, 2012
In December 2011, the President’s Bioethics Commission released its “Moral Science: Protecting Participants in Human Subjects Research.” The report was ordered by President Obama following an October 2010 revelation that the US Public Health Service supported unethical research in Guatemala from 1946 to 1948 that involved intentionally exposing thousands of Guatemalans to sexually transmitted diseases [...]
Also posted in Guest Blog, Regulatory, Safety | Tagged , , , | Leave a comment

JP Morgan Healthcare Conference Marked by Uncertainty

By Guest Blogger | Published: January 12, 2012
2012 J.P. Morgan Healthcare Conference Marked by Uncertainty Audrey S. Erbes, Principal, Erbes & Associates, outlines the highlights of this week’s event in San Francisco. One of the few positive notes struck in this week’s 30th Annual J.P. Morgan Healthcare Conference (held in San Francisco) was the announcement by Kevin Willsey, J.P. Morgan’s co-head of investment banking [...]
Also posted in Guest Blog, Strategy, healthcare | Tagged , , , , | 2 Comments

Calculating the Cost of R&D: Defending Tufts Research

By William Looney | Published: January 11, 2012
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues,  because if you cannot justify your costs how do you expect to prevail on price?   
Also posted in Op-Ed, pricing | Tagged , , , , , | 1 Comment

Not Just Numbers: R&D Decline Measured in More Than NMEs

By Jennifer Ringler | Published: December 5, 2011
The hard (declining) numbers of approved NMEs in the past 10 to 15 years tell a powerful story. But is it the whole story?
Posted in R&D | Tagged , , | 1 Comment

Patient Privacy Fears Taint UK Innovation Plans

By Julian Upton | Published: December 5, 2011
Patient Privacy Fears Taint UK Innovation Plans The Conservative arm of the UK’s coalition government flexed its private-sector-friendly muscles again on Monday with the announcement that the National Health Service should be ‘opened up’ to private healthcare firms. In a pharma-friendly speech peppered with the usual buzzwords, Prime Minister David Cameron said: “The end-game is for [...]
Also posted in healthcare | Tagged , , , , | Leave a comment